English Journal

Hyytiä H1, Heikkilä T2, Brockmann EC2, Kekki H2, Hedberg P3, Puolakanaho T3, Lövgren T2, Pettersson K2.
Clinical biochemistry.Clin Biochem.2014 Aug 8. pii: S0009-9120(14)00608-0. doi: 10.1016/j.clinbiochem.2014.06.080. [Epub ahead of print]
OBJECTIVES: To introduce a novel nanoparticle-based immunoassay for cardiac troponin I (cTnI) utilizing chimeric antibody fragments and to demonstrate that removal of antibody Fc-part and antibody chimerization decrease matrix related interferences.DESIGN AND METHODS: A sandwich-type immunoassay for
PMID 25111014

Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades.

Mak TM1, Hanson BJ2, Tan YJ3.
Antiviral research.Antiviral Res.2014 Jul;107:76-83. doi: 10.1016/j.antiviral.2014.04.011. Epub 2014 May 4.
The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed a
PMID 24797696

Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4.

Gromowski GD1, Firestone CY2, Hanson CT2, Whitehead SS2.
Vaccine.Vaccine.2014 May 23;32(25):3010-8. doi: 10.1016/j.vaccine.2014.03.062. Epub 2014 Mar 31.
Japanese encephalitis virus (JEV) is a leading cause of viral encephalitis worldwide and vaccination is one of the most effective ways to prevent disease. A suitable live-attenuated JEV vaccine could be formulated with a live-attenuated tetravalent dengue vaccine for the control of these viruses in
PMID 24699473